Suppr超能文献

针对一种靶向细胞蛋白的抑制剂,脊髓灰质炎病毒抗性的细胞特异性建立。

Cell-specific establishment of poliovirus resistance to an inhibitor targeting a cellular protein.

作者信息

Viktorova Ekaterina G, Nchoutmboube Jules, Ford-Siltz Lauren A, Belov George A

机构信息

Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA.

Department of Veterinary Medicine, University of Maryland, College Park, Maryland, USA Virginia-Maryland Regional College of Veterinary Medicine, University of Maryland, College Park, Maryland, USA

出版信息

J Virol. 2015 Apr;89(8):4372-86. doi: 10.1128/JVI.00055-15. Epub 2015 Feb 4.

Abstract

UNLABELLED

It is hypothesized that targeting stable cellular factors involved in viral replication instead of virus-specific proteins may raise the barrier for development of resistant mutants, which is especially important for highly adaptable small (+)RNA viruses. However, contrary to this assumption, the accumulated evidence shows that these viruses easily generate mutants resistant to the inhibitors of cellular proteins at least in some systems. We investigated here the development of poliovirus resistance to brefeldin A (BFA), an inhibitor of the cellular protein GBF1, a guanine nucleotide exchange factor for the small cellular GTPase Arf1. We found that while resistant viruses can be easily selected in HeLa cells, they do not emerge in Vero cells, in spite that in the absence of the drug both cultures support robust virus replication. Our data show that the viral replication is much more resilient to BFA than functioning of the cellular secretory pathway, suggesting that the role of GBF1 in the viral replication is independent of its Arf activating function. We demonstrate that the level of recruitment of GBF1 to the replication complexes limits the establishment and expression of a BFA resistance phenotype in both HeLa and Vero cells. Moreover, the BFA resistance phenotype of poliovirus mutants is also cell type dependent in different cells of human origin and results in a fitness loss in the form of reduced efficiency of RNA replication in the absence of the drug. Thus, a rational approach to the development of host-targeting antivirals may overcome the superior adaptability of (+)RNA viruses.

IMPORTANCE

Compared to the number of viral diseases, the number of available vaccines is miniscule. For some viruses vaccine development has not been successful after multiple attempts, and for many others vaccination is not a viable option. Antiviral drugs are needed for clinical practice and public health emergencies. However, viruses are highly adaptable and can easily generate mutants resistant to practically any compounds targeting viral proteins. An alternative approach is to target stable cellular factors recruited for the virus-specific functions. In the present study, we analyzed the factors permitting and restricting the establishment of the resistance of poliovirus, a small (+)RNA virus, to brefeldin A (BFA), a drug targeting a cellular component of the viral replication complex. We found that the emergence and replication potential of resistant mutants is cell type dependent and that BFA resistance reduces virus fitness. Our data provide a rational approach to the development of antiviral therapeutics targeting host factors.

摘要

未标记

据推测,靶向参与病毒复制的稳定细胞因子而非病毒特异性蛋白可能会提高耐药突变体产生的门槛,这对于适应性很强的小(+)RNA病毒尤为重要。然而,与这一假设相反,越来越多的证据表明,至少在某些系统中,这些病毒很容易产生对细胞蛋白抑制剂耐药的突变体。我们在此研究了脊髓灰质炎病毒对布雷菲德菌素A(BFA)产生耐药性的情况,BFA是一种细胞蛋白GBF1的抑制剂,GBF1是细胞小GTP酶Arf1的鸟嘌呤核苷酸交换因子。我们发现,虽然在HeLa细胞中很容易筛选出耐药病毒,但在Vero细胞中却不会出现,尽管在没有药物的情况下两种细胞培养物都能支持强劲的病毒复制。我们的数据表明,病毒复制对BFA的耐受性远高于细胞分泌途径的功能,这表明GBF1在病毒复制中的作用与其激活Arf的功能无关。我们证明,GBF1募集到复制复合物的水平限制了HeLa和Vero细胞中BFA耐药表型的建立和表达。此外,脊髓灰质炎病毒突变体的BFA耐药表型在不同的人源细胞类型中也具有细胞类型依赖性,并且在没有药物的情况下会以RNA复制效率降低的形式导致适应性损失。因此,开发靶向宿主的抗病毒药物的合理方法可能会克服(+)RNA病毒的超强适应性。

重要性

与病毒性疾病的数量相比,可用疫苗的数量微不足道。对于一些病毒,经过多次尝试疫苗开发仍未成功,而对于许多其他病毒,接种疫苗并非可行选择。临床实践和公共卫生紧急情况需要抗病毒药物。然而,病毒具有高度适应性,几乎可以轻易产生对任何靶向病毒蛋白的化合物耐药的突变体。另一种方法是靶向为病毒特异性功能募集的稳定细胞因子。在本研究中,我们分析了允许和限制小(+)RNA病毒脊髓灰质炎病毒对布雷菲德菌素A(BFA)产生耐药性的因素,BFA是一种靶向病毒复制复合物细胞成分的药物。我们发现耐药突变体的出现和复制潜力具有细胞类型依赖性,并且BFA耐药性会降低病毒适应性。我们的数据为开发靶向宿主因子的抗病毒疗法提供了合理方法。

相似文献

1
Cell-specific establishment of poliovirus resistance to an inhibitor targeting a cellular protein.
J Virol. 2015 Apr;89(8):4372-86. doi: 10.1128/JVI.00055-15. Epub 2015 Feb 4.
4
Rab1b-GBF1-ARF1 Secretory Pathway Axis Is Required for Birnavirus Replication.
J Virol. 2022 Feb 23;96(4):e0200521. doi: 10.1128/JVI.02005-21. Epub 2021 Dec 8.
5
Poliovirus replication requires the N-terminus but not the catalytic Sec7 domain of ArfGEF GBF1.
Cell Microbiol. 2010 Oct;12(10):1463-79. doi: 10.1111/j.1462-5822.2010.01482.x.
6
GBF1, a guanine nucleotide exchange factor for Arf, is crucial for coxsackievirus B3 RNA replication.
J Virol. 2009 Nov;83(22):11940-9. doi: 10.1128/JVI.01244-09. Epub 2009 Sep 9.
8
Hepatitis C virus replication and Golgi function in brefeldin a-resistant hepatoma-derived cells.
PLoS One. 2013 Sep 18;8(9):e74491. doi: 10.1371/journal.pone.0074491. eCollection 2013.
9
A critical role of a cellular membrane traffic protein in poliovirus RNA replication.
PLoS Pathog. 2008 Nov;4(11):e1000216. doi: 10.1371/journal.ppat.1000216. Epub 2008 Nov 21.
10
Poliovirus proteins induce membrane association of GTPase ADP-ribosylation factor.
J Virol. 2005 Jun;79(11):7207-16. doi: 10.1128/JVI.79.11.7207-7216.2005.

本文引用的文献

1
Regulating the large Sec7 ARF guanine nucleotide exchange factors: the when, where and how of activation.
Cell Mol Life Sci. 2014 Sep;71(18):3419-38. doi: 10.1007/s00018-014-1602-7. Epub 2014 Apr 13.
2
Mutational and fitness landscapes of an RNA virus revealed through population sequencing.
Nature. 2014 Jan 30;505(7485):686-90. doi: 10.1038/nature12861. Epub 2013 Nov 27.
5
RNA virus population diversity: implications for inter-species transmission.
Curr Opin Virol. 2011 Dec;1(6):643-8. doi: 10.1016/j.coviro.2011.09.012. Epub 2011 Oct 22.
7
Combating enterovirus replication: state-of-the-art on antiviral research.
Biochem Pharmacol. 2012 Jan 15;83(2):185-92. doi: 10.1016/j.bcp.2011.08.016. Epub 2011 Aug 26.
8
Analysis of poliovirus protein 3A interactions with viral and cellular proteins in infected cells.
J Virol. 2011 May;85(9):4284-96. doi: 10.1128/JVI.02398-10. Epub 2011 Feb 23.
9
Rhinovirus vaccination: the case against.
Eur Respir J. 2011 Jan;37(1):5-7. doi: 10.1183/09031936.00145710.
10
Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.
J Virol. 2011 Mar;85(5):2364-72. doi: 10.1128/JVI.02249-10. Epub 2010 Dec 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验